Equity Rights Offering	9 Months Ended
Sep. 30, 2025
Warrants and Rights Note Disclosure [Abstract]
Equity Rights Offering	Note 11 – Equity Rights Offering In September 2020, the Corporation completed an equity rights offering, issuing 5,507,889 shares of its common stock and 12,339,256 Series A warrants to existing shareholders. The shares of common stock and warrants are classified as equity instruments in the condensed consolidated statements of shareholders’ equity. Outstanding Series A warrants equaling 10,935,755 expired August 1, 2025 and are no longer exercisable, in accordance with the warrant agreement. Each Series A warrant provided the holder with the right to purchase 0.4464 shares of common stock at an exercise price of $2.5668, or $5.75 per whole share of common stock. During 2025, 6,114 warrants were exercised, including 5,715 warrants exercised in the third quarter of 2025.

Equity Rights Offering

9 Months Ended

Sep. 30, 2025

Warrants and Rights Note Disclosure [Abstract]

Note 11 – Equity Rights Offering

In September 2020, the Corporation completed an equity rights offering, issuing 5,507,889 shares of its common stock and 12,339,256 Series A warrants to existing shareholders. The shares of common stock and warrants are classified as equity instruments in the condensed consolidated statements of shareholders’ equity. Outstanding Series A warrants equaling 10,935,755 expired August 1, 2025 and are no longer exercisable, in accordance with the warrant agreement. Each Series A warrant provided the holder with the right to purchase 0.4464 shares of common stock at an exercise price of $2.5668, or $5.75 per whole share of common stock. During 2025, 6,114 warrants were exercised, including 5,715 warrants exercised in the third quarter of 2025.